

# **Oral Lactoferrin as a Source of Iron Supplementation in Pediatric Patients with Chronic Kidney Disease**

*Thesis*

Submitted for Partial Fulfillment of the Master  
Degree in **Pediatrics**

*By*

**Rawan Ashraf Mohamed Al-Arian**

M.B.B.ch (2012)

Faculty of Medicine-Ain Shams University

*Under Supervision of*

**Prof. Dr. Ihab Zaki El-Hakim**

Professor of Pediatrics

Faculty of Medicine-Ain Shams University

**Dr. Mohamed Samy El-Farsy**

Lecturer of Pediatrics

Faculty of Medicine-Ain Shams University

**Faculty of Medicine  
Ain Shams University  
2017**

# Acknowledgement

*First of all, all gratitude is due to **Allah** Almighty for blessing this work, until it has reached its end, as a part of his generous help, throughout my life.*

*Really I can hardly find the words to express my gratitude to **Prof. Dr. Ihab Zaki El-Hakim**, Professor of Pediatrics, Faculty of Medicine-Ain Shams University, for his supervision, continuous help, encouragement throughout this work and tremendous effort he has done in the meticulous revision of the whole work. It is a great honor to work under his guidance and supervision.*

*I would like also to express my sincere appreciation and gratitude to **Dr. Mohamed Samy El-Farsy**, Lecturer of Pediatrics, Faculty of Medicine-Ain Shams University, for his continuous directions and support throughout the whole work.*

*Last but not least, I dedicate this work to **my family**, whom without their sincere emotional support, pushing me forward this work would not have ever been completed.*



**Rawan Ashraf Mohamed Al-Arian**

# List of Contents

	Page
Acknowledgment .....	--
List of Abbreviations .....	I
List of Figures .....	III
List of Tables .....	V
Introduction .....	1
Aim of the Work .....	3
Review of Literature .....	4
<b>Chapter 1: Chronic Kidney Disease</b> .....	4
<b>Chapter 2: Anemia of Chronic Kidney Disease</b> .....	28
<b>Chapter 3: Lactoferrin</b> .....	44
Patients and Methods .....	61
Results .....	67
Discussion .....	83
Conclusion .....	90
Recommendations .....	91
Summary .....	92
References .....	94
Arabic Summary .....	--

## **List of Abbreviations**

ARBs	: Angiotensin II receptor blockers
bLF	: Bovine lactoferrin
BMI	: Body Mass Index
BUN	: Blood Urea Nitrogen
CAD	: Coronary Artery Disease
CAKUT	: Congenital abnormalities of kidney and urinary tract
CHF	: Congestive Heart Failure
CKD	: Chronic kidney disease
DMSA	: Di Mercapto Succinic Acid
eGFR	: estimated Glomerular Filtration Rate
EPO	: Erythropoietin
ESRD	: End Stage Renal Disease
5D	: End stage renal disease
GFR	: Glomerular Filtration Rate
HCV	: Hepatitis C virus
hLF	: Holo-lactoferrin
HMP	: Hexose Mono Phosphate
HS	: Heparan sulfate
IL-6	: Interleukin 6
IV	: Intravenous
IVP	: Intra Venous Pyelography
KDOQI	: Kidney Disease Outcomes Quality Initiative
LDL	: Low-density lipoprotein
LF	: Lactoferrin
LPS	: Lipopolysacchride
LVH	: Left Ventricular Hypertrophy
NCEP-C	: The National Cholesterol Expert Panel on Children
NKF	: National Kidney Foundation

## **List of Abbreviations (Cont.)**

NSAIDS	: Non Steroidal Anti Inflammatory Drugs
PCr	: Plasma Creatinine Concentration
pLf	: Porcine lactoferrin
PTH	: Parathyroid Hormone
RBC	: Red blood cell
RDA	: Recommended dietary allowance
rhGH	: recombinant Human Growth Hormone
rLf	: Recombinant lactoferrin
SDS	: Standard Deviation Scores
TPTZ	: 2,4,6-Tri-(2-pyridyl)-5-triazine

## List of Figures

<b>Fig.</b>	<b>Title</b>	<b>Page</b>
1	Autosomal recessive polycystic kidney disease	6
2	Hands of a transfusion-dependent patient on long-term hemodialysis. Several uremia-related cutaneous disorders are visible	12
3	Anemia in CKD	28
4	Mechanism of action of hepcidin	29
5	Purpura	32
6	Three-dimensional structure of biferric bovine lactoferrin at a resolution of 2.8 Angstroms	45
7	Iron uptake, transport, delivery and recycling in the human body	46
8	Mechanism of antibacterial action of lactoferrin (LF)	49
9	Mechanism of antiviral action of lactoferrin (LF)	51
10	Pie chart describing gender in patients group	68
11	Etiology of CKD among cases	68
12	Pie chart describing the stages of CKD in patients group	69
13	Serum iron ( $\mu\text{mol/L}$ ) among the studied cases	71
14	Rate of change in serum iron among the studied cases	72

<b>Fig.</b>	<b>Title</b>	<b>Page</b>
15	Serum ferritin ( $\mu\text{mol/L}$ ) among the studied cases	73
16	Rate of change in serum ferritin among the studied cases	74
17	Serum TIBC ( $\mu\text{mol/L}$ ) among the studied cases	75
18	Rate of change in serum TIBC among the studied cases	76
19	Blood Hb ( $\text{gm/dL}$ ) among the studied cases	78
20	Blood RBC ( $\times 10^{12}/\text{L}$ ) among the studied cases	80
21	Comparison between CKD stages regarding lab changes 6 months after intervention	81

## List of Tables

Table	Title	Page
1	Standardized terminology for stages of CKD	5
2	Stages of CKD	63
3	Basal demographic and clinical characteristics of the studied cases	67
4	Clinical manifestations of anemia among the studied cases	70
5	Serum iron ( $\mu\text{mol/L}$ ) among the studied cases	70
6	Rate of change in serum iron among the studied cases	71
7	Serum ferritin ( $\mu\text{mol/L}$ ) among the studied cases	72
8	Rate of change in Serum ferritin abnormality among the studied cases	73
9	Serum TIBC ( $\mu\text{mol/L}$ ) among the studied cases	75
10	Rate of change in Serum TIBC among the studied cases	76
11	Blood Hb (gm/dL) among the studied cases	77
12	Blood RBC ( $\times 10^{12}/\text{L}$ ) among the studied cases	79
13	Comparison between CKD stages regarding lab changes 6 months after intervention	81
14	Side effects among the studied cases	82





---

# Introduction

---





---

# **Aim of the Work**

---





---

# **Review of Literature**

---





---

## **Anemia of Chronic Kidney Disease**

---





---

## **Chronic Kidney Disease**

---





---

## **Lactoferrin**

---





---

# **Patients and Methods**

---

